G007-LK: Precise Tankyrase 1/2 Inhibitor for Wnt/β-catenin and APC Mutation Cancer Research

Executive Summary: G007-LK is a small-molecule inhibitor with nanomolar potency against tankyrase 1 (TNKS1) and tankyrase 2 (TNKS2) (IC₅₀: 46 nM and 25 nM, respectively) [APExBIO]. It blocks auto-poly(ADP-ribosyl)ation, suppresses Wnt/β-catenin pathway signaling in multiple cancer models, and induces β-catenin degradation in APC-mutant colorectal cancer cells (Jia et al., 2017). G007-LK also stabilizes AXIN1/2 and upregulates AMOTL1/2, leading to YAP/TAZ downregulation via Hippo pathway modulation. In vivo, G007-LK reduces tumor growth in xenograft models by suppressing TNKS1/2 and β-catenin. It is a critical research tool for studying tankyrase function, Wnt/β-catenin signaling, and cancer biology, especially in colorectal and hepatocellular carcinoma contexts.

Biological Rationale

Tankyrases (TNKS1 and TNKS2) are poly(ADP-ribose) polymerases (PARPs) that regulate diverse cellular processes, including Wnt/β-catenin signaling, telomere maintenance, and mitosis [Jia et al., 2017]. Aberrant tankyrase activity is implicated in oncogenesis, notably in colorectal and hepatocellular carcinomas, where dysregulated Wnt/β-catenin and Hippo pathways drive proliferation and tumor progression. APC mutations, frequent in colorectal cancer, lead to β-catenin accumulation and Wnt pathway hyperactivation. Inhibiting tankyrase activity restores AXIN1/2 stability, enabling β-catenin degradation and attenuating oncogenic signaling [related analysis]. G007-LK is designed as a highly selective tankyrase inhibitor for dissecting these pathways in model systems.

Mechanism of Action of G007-LK tankyrase 1/2 inhibitor

G007-LK binds to the catalytic PARP domain of TNKS1 and TNKS2, blocking their auto-poly(ADP-ribosyl)ation activity (IC₅₀ values: 46 nM for TNKS1, 25 nM for TNKS2) [product info]. This inhibition prevents PAR-dependent ubiquitination and degradation of AXIN1/2, leading to stabilization of the β-catenin destruction complex. In Wnt3a-stimulated HEK293 cells, G007-LK suppresses Wnt signaling (reporter ST-Luc IC₅₀: 0.05 μM). In APC-mutant colorectal cancer cell lines (e.g., SW480), it induces degradasome formation with phosphorylated β-catenin, β-TrCP, and ubiquitin, reducing cytosolic and nuclear β-catenin concentrations. G007-LK also increases AMOTL1/2 protein levels, suppressing YAP/TAZ activity by enhancing Hippo pathway output [Jia et al., 2017].

Evidence & Benchmarks

• G007-LK inhibits TNKS1 and TNKS2 auto-poly(ADP-ribosyl)ation with IC₅₀ values of 46 nM and 25 nM, respectively (APExBIO, product page).
• Suppresses Wnt signaling in Wnt3a-induced HEK293 cells with an ST-Luc reporter IC₅₀ of 0.05 μM (APExBIO, product page).
• Induces β-catenin degradasomes and decreases β-catenin in cytosolic and nuclear fractions of APC-mutant colorectal cancer lines (SW480) (Jia et al., 2017).
• Reduces tumor growth in COLO-320DM xenograft mouse models and decreases TNKS1/2, β-catenin proteins, while stabilizing AXIN1/2 (Jia et al., 2017).
• Upregulates AMOTL1/2, leading to YAP/TAZ downregulation in hepatocellular carcinoma cells (Jia et al., 2017, Figs 2–4).
• Synergizes with MEK and AKT inhibitors to further suppress cancer cell proliferation (Jia et al., 2017, Table 1).

This article builds on prior discussions of G007-LK’s molecular specificity by providing updated evidence of its Hippo pathway modulation and in vivo efficacy benchmarks.

Applications, Limits & Misconceptions

G007-LK is primarily used for:

• Dissecting Wnt/β-catenin signaling in APC-mutant colorectal cancer research.
• Investigating Hippo pathway modulation via YAP/TAZ downregulation in hepatocellular carcinoma.
• Studying poly(ADP-ribosyl)ation-dependent processes related to cancer, inflammation, and metabolic regulation.
• Preclinical testing of combinatorial regimens with MEK or AKT inhibitors.

Compared to basic overviews of G007-LK’s selectivity, this article provides direct evidence for its effects on AMOTL1/2 stabilization and YAP target gene repression.

Common Pitfalls or Misconceptions

• G007-LK is not effective in models where Wnt/β-catenin signaling is not tankyrase-dependent.
• It does not inhibit PARP1 or other PARP family members; specificity is limited to TNKS1/2.
• β-catenin-independent colorectal tumors may not respond to G007-LK.
• G007-LK is not a therapeutic drug; it is for research use only.
• Solubility is poor in water and ethanol; improper preparation may cause precipitation or reduced efficacy.

This perspective extends previous translational strategy articles by clarifying these practical and mechanistic boundaries.

Workflow Integration & Parameters

• Storage: G007-LK should be kept as a solid at -20°C. Avoid long-term storage of solutions (APExBIO).
• Solubility: Soluble at ≥26.5 mg/mL in DMSO; insoluble in water and ethanol. For full dissolution, warm at 37°C or use an ultrasonic bath.
• Cellular Assays: Typical working concentrations range from 0.01–1 μM for in vitro cell-based assays.
• Animal Models: Dosing in murine xenograft studies should follow established protocols, with attention to vehicle formulation for bioavailability and tolerability (Jia et al., 2017).
• Controls: Include Wnt pathway agonists/antagonists as positive/negative controls to validate pathway specificity.

For detailed protocols and advanced experimental design, refer to the G007-LK tankyrase 1/2 inhibitor product page and recent in-depth reviews.

Conclusion & Outlook

G007-LK, offered by APExBIO, is a benchmark tool for the study of tankyrase-mediated signaling, particularly in Wnt/β-catenin and Hippo pathway-driven cancers. Its nanomolar potency, selectivity, and proven in vivo efficacy empower researchers to dissect β-catenin degradation, AXIN1/2 stabilization, and YAP/TAZ regulation with precision. As evidence accumulates for its use in combinatorial regimens and new model systems, G007-LK is poised to remain central in cancer biology research. Future applications may include further mechanistic dissection in stem cell biology, tissue regeneration, and resistance pathways.